

# World Journal of *Hepatology*

*World J Hepatol* 2018 October 27; 10(10): 639-784



**EDITORIAL**

- 639 European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift

*Loustaud-Ratti V, Debette-Gratien M, Carrier P*

**REVIEW**

- 645 Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma

*Krivtsova O, Makarova A, Lazarevich N*

- 662 Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis

*Lin CJ, Hu ZG, Yuan GD, Lei B, He SQ*

**MINIREVIEWS**

- 670 Era of direct acting anti-viral agents for the treatment of hepatitis C

*Ahmed M*

- 685 Nutritional support in chronic liver disease and cirrhotics

*Shergill R, Syed W, Rizvi SA, Singh I*

- 695 Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review

*Almeida NS, Rocha R, Cotrim HP, Daltro C*

- 702 Dental pulp cell bank as a possible future source of individual hepatocytes

*Ohkoshi S, Hirono H, Nakahara T, Ishikawa H*

- 708 Adiponectin as a novel biomarker for liver fibrosis

*Udomsinprasert W, Honsawek S, Poovorawan Y*

**ORIGINAL ARTICLE****Basic Study**

- 719 Experimental bio-artificial liver: Importance of the architectural design on ammonia detoxification performance

*Pizarro MD, Mamprin ME, Daurelio LD, Rodriguez JV, Mediavilla MG*

**Retrospective Cohort Study**

- 731 Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients

*Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, Azzaroli F, Brilli S, Mazzella G, Festi D*

**EVIDENCE-BASED MEDICINE**

- 743 Comparison of hepatitis C virus testing recommendations in high-income countries  
*Irvin R, Ward K, Agee T, Nelson NP, Vellozzi C, Thomas DL, Millman AJ*

**SYSTEMATIC REVIEW**

- 752 Thrombosis prophylaxis in pediatric liver transplantation: A systematic review  
*Nacoti M, Ruggeri GM, Colombo G, Bonanomi E, Lussana F*

**META-ANALYSIS**

- 761 Liver transplantation and atrial fibrillation: A meta-analysis  
*Chokesuwattanaskul R, Thongprayoon C, Bathini T, Ungprasert P, Sharma K, Wijarnpreecha K, Pachariyanon P, Cheungpasitporn W*

**CASE REPORT**

- 772 Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature  
*Lin YL*
- 780 Neuroendocrine tumor incidentally detected during living donor hepatectomy: A case report and review of literature  
*Akbulut S, Isik B, Cicek E, Samdanci E, Yilmaz S*

**ABOUT COVER**

Editorial Board Member of *World Journal of Hepatology*, Seren Ozenirler, MD, Professor, Gazi University Department of Gastroenterology and Hepatology, Besevler, Ankara 06510, Turkey

**AIM AND SCOPE**

*World Journal of Hepatology* (*World J Hepatol*, *WJH*, online ISSN 1948-5182, DOI: 10.4254), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJH* covers topics concerning liver biology/pathology, cirrhosis and its complications, liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. Priority publication will be given to articles concerning diagnosis and treatment of hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING**

*World Journal of Hepatology* (*WJH*) is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), and Superstar Journals Database.

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Han Song*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ying Dou*  
Proofing Editorial Office Director: *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Hepatology*

**ISSN**  
ISSN 1948-5182 (online)

**LAUNCH DATE**  
October 31, 2009

**FREQUENCY**  
Monthly

**EDITORIAL BOARD MEMBERS**  
All editorial board members resources online at <http://www.wjgnet.com/1948-5182/editorialboard.htm>

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director  
*World Journal of Hepatology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,

Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
October 27, 2018

**COPYRIGHT**

© 2018 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**

<http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**

<http://www.f6publishing.com>

## Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis

Cheng-Jie Lin, Zhi-Gao Hu, Guan-Dou Yuan, Biao Lei, Song-Qing He

Cheng-Jie Lin, Zhi-Gao Hu, Guan-Dou Yuan, Biao Lei, Song-Qing He, Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

ORCID number: Cheng-Jie Lin (0000-0003-3194-0380); Zhi-Gao Hu (0000-0003-0575-2191); Guan-Dou Yuan (0000-0002-4758-1928); Biao Lei (0000-0003-3354-5173); Song-Qing He (0000-0002-8966-2195).

**Author contributions:** Lin CJ and Hu ZG contributed equally to this work; He SQ designed research; Lin CJ, Hu ZG and Yuan GD searched the relevant literatures; and Lin CJ wrote the review; Lei B and He SQ revised the review.

**Supported by** State Key Program of National Natural Science Foundation of China, No. 8143000311; National Natural Science Foundation of China, No. 81660103 and No. 81771674; 111 Project, No. D17011; Guangxi BaGui Scholars; the Natural Science Foundation of Guangxi Province, No. 2015GXNSFFA139004.

**Conflict-of-interest statement:** All authors have no conflicts of interest to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Song-Qing He, PhD, Chief Doctor, Professor, Research Professor, Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. [dr\\_hesongqing@163.com](mailto:dr_hesongqing@163.com)  
Telephone: +86-771-5356568

Received: April 10, 2018

Peer-review started: April 10, 2018

First decision: May 17, 2018

Revised: July 26, 2018

Accepted: August 1, 2018

Article in press: August 1, 2018

Published online: October 27, 2018

### Abstract

The complement system is a key component of the body's immune system. When abnormally activated, this system can induce inflammation and damage to normal tissues and participate in the development and progression of a variety of diseases. In the past, many scholars believed that alcoholic liver disease (ALD) is induced by the stress of ethanol on liver cells, including oxidative stress and dysfunction of mitochondria and protease bodies, causing hepatocyte injury and apoptosis. Recent studies have shown that complement activation is also involved in the genesis and development of ALD. This review focuses on the roles of complement activation in ALD and of therapeutic intervention in complement-activation pathways. We intend to provide new ideas on the diagnosis and treatment of ALD.

**Key words:** Alcoholic liver disease; Complement system proteins; Complement regulator; Liver cells; Hepatocyte injury

© **The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this review, we cited evidence that the complement system is involved in the pathogenesis of each stage of alcoholic liver disease (ALD) that include fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis, and we also summarized the complement regulation in ALD. We intend to provide new ideas on the treatment of ALD.

Lin CJ, Hu ZG, Yuan GD, Lei B, He SQ. Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis. *World J Hepatol* 2018; 10(10): 662-669 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v10/i10/662.htm> DOI: <http://dx.doi.org/10.4254/wjgh.v10.i10.662>

## INTRODUCTION

Liver disease caused by long-term excessive ethanol drinking is a major cause of chronic liver disease. As the global incidence of alcoholic liver disease (ALD) increases year by year, it has become a serious threat to human health. Almost all heavy drinkers have fatty liver, 10%-20% of which develop into alcoholic hepatitis, cirrhosis, and even hepatocellular carcinoma<sup>[1]</sup>. Exploration of the mechanisms of alcohol-induced liver injury and repair is extremely important in developing methods for preventing and treating ALD.

The complement system plays an important beneficial role in the immune system: Complement activation promotes target-cell lysis, with the associated elimination of exogenous pathogens. Yet, the complement system is a "double-edged sword", as the excessive activation of complement can induce inflammation and lead to autoimmune diseases, such as autoimmune kidney disease, glomerular nephritis, acute lung injury, and others<sup>[2-5]</sup>. Most plasma complement components are synthesized in liver cells. Thus, the liver becomes the main target of damage by complement activation<sup>[6-8]</sup>. This connection is likely due to the direct effects of alcohol that activate complement, but not because the liver is a major producer of complement proteins. Several studies have illustrated that complement activation is involved in the development of ALD<sup>[8-14]</sup> (Table 1).

## METABOLIC PATHWAYS OF ETHANOL

Most ingested ethanol is absorbed into the blood circulation, and soon reaches each organ of the body. About 90% of the ingested ethanol is metabolized in the liver<sup>[15]</sup>, and most is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase to form acetic acid, which can be used as substrate in the tricarboxylic acid cycle to produce energy. With excessive drinking, the body can activate another metabolic pathway, *i.e.*, the microsomal ethanol oxidation system (MEOS), which catalyzes ethanol mainly by cytochrome P450 2E1 in Kupffer cells. The MEOS can over produce reactive oxygen species and reactive nitrogen species, which may exceed the body's antioxidant capacity. Free radicals produced *via* the MEOS pathway exert a series of toxic effects: Membrane-lipid peroxidation, intracellular protease degeneration, oxidative modification of DNA, and others, which eventually lead to necrosis or apoptosis of hepatocytes<sup>[14,16-18]</sup>. A small percentage of ethanol is metabolized by fatty acid ethyl ester synthase to produce fatty acid ethyl ester through the non-oxidative pathway.

Fatty acid ethyl ester has cytotoxicity, which can further injure the liver and pancreas<sup>[19]</sup>. Thus the liver becomes the main organ damaged by ethanol. Chronic ethanol exposure results in decreased protease activity in liver cells, imbalance of the liver's detoxification function, and overproduction of acetaldehyde, thus inducing hepatic oxidative stress and complement activation; all these activities can injure hepatocytes<sup>[20]</sup>.

## COMPLEMENT ACTIVATION PATHWAY

The complement system consists of more than 30 kinds of proteins with enzyme-like activities which are inherent components, regulatory proteins, and complement receptors. Complement regulatory proteins include plasma soluble factors, membrane binding proteins, homologous restriction factor, and membrane inhibitors of reactive lysis. Because the complement system is involved in inflammation and immune regulation, it plays an important role in regulation of pathophysiological functions<sup>[21]</sup>.

Complement is activated by three pathways: The classical, mannan-binding lectin (MBL), and alternative pathways. The three pathways start with different mechanisms, but they end with a common terminal pathway, as shown in Figure 1. The classical pathway is the main mechanism of immune responses. In it, C1q identifies immune complexes, followed by the activation of C1r and C1s. Activated C1s cleaves C2 and C4 to form C3 convertase (C4bC2a), which cleaves C3 to form C5 convertase (C4bC2aC3b). In contrast to activation of the classical pathway, activation of the lectin pathway does not depend on immune complexes. In this pathway, the cascade of enzymatic reactions proceeds in this sequence: MBL identifies the pathogens to form MBL-associated serine proteases (MASP1, MASP2); MASP1 directly cleaves C3 to form C3 convertase (C3bBb), MASP2 cleaves C4 and C2 in a manner similar to that of C1s, forming C3 convertase (C4bC2a), which continues to cleave C5 to form C5 convertase (C4bC2aC3b). Thus, this pathway can cross-promote the classical and alternative pathways. The alternative pathway is activated with hydrolysis of C3 into C3(H<sub>2</sub>O), factor B and factor D, the activation of which is also independent of immune complexes, and participates in the defense mechanisms of the early stage of inflammation<sup>[13,22-24]</sup>. The above three pathways merge into the terminal pathway, in which C5 convertase cleaves C5 to form C5a and C5b, and C5b combines with C6, C7, C8 and C9 to form the membrane attack complex (MAC). Formation of the MAC leads to cell lysis and induces cells to release inflammatory cytokines.

## COMPLEMENT ACTIVATION IN ALD

ALD progresses in three distinct stages: Fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis. In this review, we cite evidence that the complement system is involved

**Table 1** Important publications on complement in alcoholic liver disease

Study	Complement component	Alcoholic liver disease	Species
Järveläinen <i>et al</i> <sup>[10]</sup>	C1, Crry, CD59	Alcohol-induced injury	Rat
Bykov <i>et al</i> <sup>[11]</sup>	C3	Liver steatosis	Mouse
Pritchard <i>et al</i> <sup>[8]</sup>	C3, C5, DAF	Fatty liver	Mouse
He <i>et al</i> <sup>[7]</sup>	C3	Liver steatosis	Mouse
Cohen <i>et al</i> <sup>[13]</sup>	C1q	Alcohol-induced injury	Mouse
Wlazlo <i>et al</i> <sup>[27]</sup>	C3	Liver steatosis	Human
Shen <i>et al</i> <sup>[6]</sup>	C3	Alcoholic hepatitis	Mouse
Maslowska <i>et al</i> <sup>[30]</sup>	Factor D	Alcoholic hepatitis	Mouse

Crry: Complement receptor 1-related protein y; DAF: Decay accelerating factor.

in the pathogenesis of each of these stages.

### Complement activation in alcoholic fatty liver disease

The liver is the main site of fat metabolism. Disorders of fat metabolism, caused by various factors, can lead to excessive fat accumulation in the liver cells, *i.e.*, fatty liver. Long-term heavy drinking is the main independent risk factor of fatty liver disease<sup>[25]</sup>, but its pathogenesis is not clearly defined. Liu *et al*<sup>[26]</sup> found that gut microbiota played a synergistic role in the liver response, and the complement system was suppressed in fatty liver which was partially due to increased blood lactic acid from enriched *Lactobacillus*. Abnormal complement activation reportedly enhances the sensitivity of steatotic livers to ischemia and reperfusion injury, which leads to the development of fatty liver<sup>[27,28]</sup>. Järveläinen *et al*<sup>[10]</sup> found that deposition of complement C1, C3, and C8 was increased, and the expression of membrane-binding proteins, complement receptor 1-related protein y (Crry), and CD59 was decreased in the liver cells of a mouse ALD model. These findings proved that alcohol-induced complement activation can result in ALD, at least in an experimental model. In a study in mice chronically exposed to ethanol, Cohen *et al*<sup>[13]</sup> found that lipid deposition in liver cells as well as values of liver-related serum enzymes (alanine aminotransferase and aspartate amino transferase) increased significantly; various degrees of liver cell apoptosis were also found. Moreover, with knock out of the C1q gene, hepatic steatosis in the mice was significantly decreased<sup>[13]</sup>. This study illustrated that complement activation could be associated with ethanol-induced hepatic steatosis.

Bykov *et al*<sup>[11]</sup> fed C3+/+ and C3-/- mice a high fat and high alcohol diet, respectively, and found that hepatic steatosis and significant increases in triglyceride values occurred in the C3+/+mice, whereas C3-/-mice were protected from ethanol-induced liver injury; research by Stewart *et al*<sup>[9]</sup> yielded similar results.

At the complement activation pathways, C3a converted to C3adesAg, C3adesArg which known as acylation stimulating protein had been shown to have lipogenic activity *via* its receptor C5L2, and promoted

triglyceride storage in adipocytes<sup>[29,30]</sup>. It was also found that C3adesArg was involved in the triglyceride metabolism<sup>[31]</sup>.

Thus, activation of complement C1 and C3 appears to play a significant role in promoting fatty accumulation in the liver. Further definition of the relationship between activated complement C1, C3 and lipid metabolism in the liver may aid in the development of methods for intervention and treatment of alcoholic fatty liver disease. Besides C1 and C3, complement C5 also is involved in lipid metabolism. Bavia *et al*<sup>[32,33]</sup> found that the activation of complement C5 by high-dose ethanol exposure can affect the distribution of lipid in liver cells and serum. Less lipid and cholesterol is deposited in hepatocytes of C5- mice than in hepatocytes of C5+mice, and values of IL-17, which are involved in the synthesis and metabolism of lipid and cholesterol, are higher in C5-mice than in C5+mice<sup>[34,35]</sup>. The above-cited reports indicate that activation of C5 may play a role in the development of alcoholic fatty liver.


### Complement activation in alcoholic hepatitis

ALD has many potential pathogenic factors, such as endotoxin, which may lead to complement activation and deposition in the liver cells. Shen *et al*<sup>[6]</sup> found that complement activation was involved in humans with ALD. Cohen *et al*<sup>[13]</sup> found that long-term alcohol exposure can lead to apoptosis of liver cells, and the degree of apoptosis is positively correlated with liver injury. However, whether short-term alcohol exposure can cause hepatocyte apoptosis was not known. Further research found that short-term alcohol exposure did not cause hepatocyte apoptosis, but it did promote the deposition of complement C3b and the expression of inflammatory cytokines (tumor necrosis factor and IL6). After the Cq gene was knocked out, the expression of inflammatory cytokines was significantly reduced compared to that in wild-type animals<sup>[12,13]</sup>. Experiments by Païdassi *et al*<sup>[36]</sup> and Lu *et al*<sup>[37]</sup> supported these observations.

Complement C5, a core component of the complement activation pathway, is involved in the occurrence and development of alcoholic hepatitis, in addition to fatty liver<sup>[6,8,38]</sup>. Bavia *et al*<sup>[38]</sup> documented this in a hepatitis model induced by alcohol; they found that values of pro-inflammatory cytokines (IL-6, IFN- $\gamma$ , IL-1 $\beta$ , and others) in B6C5+ mice were significantly higher than those in B6C5- mice, and anti-inflammatory factors (IL10 and IL17) were secreted significantly more in B6C5- mice. These findings illustrated that activated C5 induced the expression of proinflammatory cytokines after alcohol exposure. Up-regulated expression of pro-inflammatory cytokines (IL-6, IFN- $\gamma$ , IL-1 $\beta$ , and others) aids the body's defense against pathogenic microorganisms, but it also participates in the pathogenesis of alcoholic fatty liver and alcoholic hepatitis<sup>[8,39-41]</sup>.

### Complement activation in alcoholic hepatic fibrosis

Intrahepatic inflammatory reaction and a decrease



**Figure 1 Complement activation pathway and regulation.** Three pathways (classical, pathway, mannan-binding lectin, and alternative) are involved in complement activation. Green arrows without a red line indicate the process of complement activation. Green arrows with red line indicate the the process of inhibiting complement activation. MBL: Mannan-binding lectin; MASP: MBL-associated proteases; FB: Factor B; FH: Factor H; FI: Factor I.

in structural integrity of hepatic sinusoidal endothelial cells after long-term alcohol exposure are important inducements to liver injury. Sinusoidal endothelial cells express C5R1, which is the foundation of C5 activation-induced alcoholic hepatic fibrosis<sup>[42]</sup>. In recent years, the pathogenesis of alcoholic hepatic fibrosis has attracted worldwide attention, but the cause of the fibrosis is still not fully defined<sup>[43-45]</sup>. According to published reports<sup>[46,47]</sup>, complement C3, C4 and activation of the MBL pathway are involved in the development of fibrosis. Bavia *et al.*<sup>[38]</sup> using the mouse model of ALD, found that values of TGF- $\beta$ , which promotes hepatic fibrosis, were significantly higher in B6C5+ mice than in B6C5- mice<sup>[38,48]</sup>. Hillebradt *et al.*<sup>[49]</sup> found that the C5 gene was involved in the regulation of hepatic fibrosis on human chromosome, and further study found that C5- mice had decreased hepatic fibrosis. Thus, the evidence indicates that activation of complement C5 may promote hepatic fibrosis. Exploration of the relationship between complement activation and alcoholic hepatic fibrosis, and of possible intervention in ALD by reversing the progression of hepatic fibrosis in its early stage, seems worthwhile goals.

#### Complement-induced Kupffer cells activation in ALD

Kupffer cells, located in liver sinusoids, are an important

part of the mononuclear phagocyte system. Alcohol exposure in the early stage can promote apoptosis of Kupffer cells, but longer exposure usually is needed<sup>[13,50,51]</sup>. Ethanol-induced activation of complement component C1q at the early stage of ALD promotes the release of inflammatory cytokines from Kupffer cells, which further promote alcoholic liver injury<sup>[51-56]</sup>. Furthermore, Kupffer cells can express C3R and C5R, then induce prostaglandin release and synthesis of pro-inflammatory cytokines<sup>[57-60]</sup>. However, in certain pathological conditions, activated C5 combines with C5R, inducing the upregulation of fibrinogen on Kupffer cells, an interaction that is believed to lead to hepatic fibrosis<sup>[22,61]</sup>. In addition, alcohol-induced upregulation of CD14 leads to Kupffer cells combining with lipopolysaccharide, which induces liver damage through the activation of TLR4 in Kupffer cells and inflammatory signaling pathways; these events can further aid in the development of hepatic fibrosis or cirrhosis<sup>[62]</sup>. Thus, Kupffer cells seem to be extensively involved in the development of ALD<sup>[63-66]</sup>.

#### COMPLEMENT REGULATION IN ALD

Reducing inflammatory reactions by inhibiting amplification of the complement cascade and blocking the

**Table 2** Complement regulators

Type of regulators	Regulators	Functions
Complement regulatory protein	DAF/CD55, Crry, FH, FI	Inhibit C3, C5 convertase
Complement inhibitor	CD59, protein S, clusterin	Inhibit MAC
Targeted inhibitor	C1-INH	Inhibit C1r, C1s
RNA aptamer	h5G1, 1-ScFv	Inhibit C5 activation
	Specifically bind C1q, C5	

DAF: Decay accelerating factor; Crry: Complement receptor 1-related protein y; FH: Factor H; FI: Factor I; MAC: Membrane attack complex.

combination of complement with the corresponding complement receptors are being pursued worldwide. Excessive activation of complement can be inhibited by self-regulation of the body (Table 2). For example, the complement regulatory protein decay accelerating factor (DAF) can inhibit C3, C5 convertase, thereby inhibiting amplification of the complement cascade. The complement regulatory protein Crry can cooperate with DAF and factor H to accelerate dissociation of C3 and C5 convertase and to cleave C3b and C4b, so that the cells avoid being attacked by autologous complement<sup>[67-69]</sup>. Deficiency of CD55/DAF and complement regulatory factors aggravate liver injury<sup>[8,11]</sup>, whereas factor H can control the activity and stability of C3 convertase *via* binding with C3b<sup>[70,71]</sup>. Also, defects in the factor H gene can cause persistent activation of complement pathways and trigger various diseases<sup>[72-75]</sup>. By contrast, factor H-related proteins (FHRs), including FHR1-5, can either promote or inhibit complement activation. The degree of complement activation depends on the homeostasis between factor H and FHR<sup>[71]</sup>. However, the relationship between factor H and ALD has not been clarified and needs further research. McCullough *et al.*<sup>[76]</sup> found FD-dependent amplification of complement is an adaptive response that promotes hepatic healing and recovery in response to chronic ethanol. In other complement regulatory activities, CD59, protein S and clusterin inhibit the formation of the MAC through limiting the binding of complement C9<sup>[77-81]</sup>. Membrane cofactor protein (MCP) and factor I can inhibit cells from binding with C3b and C4b<sup>[82,83]</sup>.

Specific epitope structures of complement, such as anti-complement antibody, complement antisense strand, and complement mutants<sup>[84-91]</sup> have been invented, with the intent of inhibiting complement activation. In addition, complement inhibitors and RNA aptamer are being used to inhibit progression of complement-related diseases<sup>[92,93]</sup>, and C1-INH and CR1 have been used in the treatment of ALD and other diseases<sup>[10]</sup>.

## CONCLUSION

Mounting evidence indicates that complement activation is involved in the development of ALD at all its stages - fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis. Moreover, all three pathways of complement activation (classical, MBL, and alternative) promote

the development of ALD. Therapeutic strategies, using various measures to inhibit complement activation, might prevent the development of ALD. Thorough understanding of the relationships between complement activation and ALD may aid in developing new approaches for the treatment of ALD.

## REFERENCES

- Warren KR, Murray MM. Alcoholic liver disease and pancreatitis: global health problems being addressed by the US National Institute on Alcohol Abuse and Alcoholism. *J Gastroenterol Hepatol* 2013; **28** Suppl 1: 4-6 [PMID: 23855288 DOI: 10.1111/jgh.12246]
- Yang Y. Mannose Binding Lectin and kidney disease. *Int J Nephrol Urol* 2010; **30**: 241-244 [DOI: 10.3760/cma.j.issn.1673-4416.2010.0.2.029]
- Borza DB. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. *Matrix Biol* 2017; **57-58**: 299-310 [PMID: 27609404 DOI: 10.1016/j.matbio.2016.09.002]
- Russkamp NF, Ruemmler R, Roewe J, Moore BB, Ward PA, Bosmann M. Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin. *FASEB J* 2015; **29**: 3762-3772 [PMID: 25999468 DOI: 10.1096/fj.15-271635]
- Reichhardt MP, Meri S. Intracellular complement activation-An alarm raising mechanism? *Semin Immunol* 2018 [PMID: 29631809 DOI: 10.1016/j.smim.2018.03.003]
- Shen H, French BA, Liu H, Tillman BC, French SW. Increased activity of the complement system in the liver of patients with alcoholic hepatitis. *Exp Mol Pathol* 2014; **97**: 338-344 [PMID: 25217811 DOI: 10.1016/j.yexmp.2014.09.004]
- He S, Atkinson C, Evans Z, Ellett JD, Southwood M, Elvington A, Chavin KD, Tomlinson S. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. *J Immunol* 2009; **183**: 4764-4772 [PMID: 19752222 DOI: 10.4049/jimmunol.0900550]
- Pritchard MT, McMullen MR, Stavitsky AB, Cohen JI, Lin F, Edward Medof M, Nagy LE. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. *Gastroenterology* 2007; **132**: 1117-1126 [PMID: 17383432 DOI: 10.1053/j.gastro.2007.01.053]
- Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. *Trends Mol Med* 2001; **7**: 408-413 [PMID: 11530336 DOI: 10.1016/S1471-4914(01)02096-2]
- Järveläinen HA, Väkevä A, Lindros KO, Meri S. Activation of complement components and reduced regulator expression in alcohol-induced liver injury in the rat. *Clin Immunol* 2002; **105**: 57-63 [PMID: 12483994 DOI: 10.1006/clim.2002.5267]
- Bykov I, Junnikkala S, Pekna M, Lindros KO, Meri S. Complement C3 contributes to ethanol-induced liver steatosis in mice. *Ann Med* 2006; **38**: 280-286 [PMID: 16754259 DOI: 10.1080/07853890600664608]
- Cohen JI, Roychowdhury S, DiBello PM, Jacobsen DW, Nagy LE.

- Exogenous thioredoxin prevents ethanol-induced oxidative damage and apoptosis in mouse liver. *Hepatology* 2009; **49**: 1709-1717 [PMID: 19205032 DOI: 10.1002/hep.22837]
- 13 **Cohen JI**, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. *Gastroenterology* 2010; **139**: 664-674, 674.e1 [PMID: 20416309 DOI: 10.1053/j.gastro.2010.04.041]
  - 14 **Orman ES**, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. *J Gastroenterol Hepatol* 2013; **28** Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]
  - 15 **Zhao J**. The metabolism and harm of alcohol. *Keji & Shenghuo* 2011; **6**: 195-198
  - 16 **Kawaratani H**, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M, Fukui H. The effect of inflammatory cytokines in alcoholic liver disease. *Mediators Inflamm* 2013; **2013**: 495156 [PMID: 24385684 DOI: 10.1155/2013/495156]
  - 17 **Cohen JI**, Chen X, Nagy LE. Redox signaling and the innate immune system in alcoholic liver disease. *Antioxid Redox Signal* 2011; **15**: 523-534 [PMID: 21126203 DOI: 10.1089/ars.2010.3746]
  - 18 **Leung TM**, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. *J Hepatol* 2013; **58**: 395-398 [PMID: 22940046 DOI: 10.1016/j.jhep.2012.08.018]
  - 19 **Cohen JI**, Nagy LE. Pathogenesis of alcoholic liver disease: interactions between parenchymal and non-parenchymal cells. *J Dig Dis* 2011; **12**: 3-9 [DOI: 10.1111/j.1751-2980.2010.00468.x]
  - 20 **Nagy LE**. The Role of Innate Immunity in Alcoholic Liver Disease. *Alcohol Res* 2015; **37**: 237-250 [PMID: 26695748]
  - 21 **Ricklin D**, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. *Nat Immunol* 2010; **11**: 785-797 [PMID: 20720586 DOI: 10.1038/ni.1923]
  - 22 **Qin X**, Gao B. The complement system in liver diseases. *Cell Mol Immunol* 2006; **3**: 333-340
  - 23 **Vieyra MB**, Heeger PS. Novel aspects of complement in kidney injury. *Kidney Int* 2010; **77**: 495-499 [PMID: 20016462 DOI: 10.1038/ki.2009.491]
  - 24 **He W**. Medical immunology. Beijing: People's Medical Publishing House; 2010: 76-91
  - 25 **Roercke M**, Nanau R, Rehm J, Neuman M. Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. *EBioMedicine* 2016; **8**: 317-330 [PMID: 27428441 DOI: 10.1016/j.ebiom.2016.04.023]
  - 26 **Liu L**, Zhao X, Wang Q, Sun X, Xia L, Wang Q, Yang B, Zhang Y, Montgomery S, Meng H, Geng T, Gong D. Prosteatotic and Protective Components in a Unique Model of Fatty Liver: Gut Microbiota and Suppressed Complement System. *Sci Rep* 2016; **6**: 31763 [PMID: 27550859 DOI: 10.1038/srep31763]
  - 27 **Wlazlo N**, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen CJ, Schalkwijk CG, Bravenboer B, Stehouwer CD. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. *Eur J Clin Invest* 2013; **43**: 679-688 [PMID: 23586841 DOI: 10.1111/eci.12093]
  - 28 **Copenhaver M**, Yu CY, Hoffman RP. Complement Components, C3 and C4, and the Metabolic Syndrome. *Curr Diabetes Rev* 2018 [PMID: 29663892 DOI: 10.2174/1573399814666180417122030]
  - 29 **Gupta A**, Rezvani R, Lapointe M, Poursharifi P, Marceau P, Tiwari S, Tchernof A, Cianflone K. Downregulation of complement C3 and C3aR expression in subcutaneous adipose tissue in obese women. *PLoS One* 2014; **9**: e95478 [PMID: 24743347 DOI: 10.1371/journal.pone.0095478]
  - 30 **Maslowska M**, Wang HW, Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. *Vitam Horm* 2005; **70**: 309-332 [PMID: 15727809 DOI: 10.1016/S0083-6729(05)70010-8]
  - 31 **Kalant D**, Phélis S, Fielding BA, Frayn KN, Cianflone K, Sniderman AD. Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. *J Lipid Res* 2000; **41**: 1963-1968 [PMID: 11108729]
  - 32 **Bavia L**, de Castro ÁA, Massironi SM, Isaac L. Basal physiological parameters of two congenic mice strains: C5 deficient C57BL/6 and C5 sufficient A/J. *Immunol Lett* 2014; **159**: 47-54 [PMID: 24607390 DOI: 10.1016/j.imlet.2014.02.010]
  - 33 **Bavia L**, de Castro ÁA, Isaac L. C57BL/6 and A/J Mice Have Different Inflammatory Response and Liver Lipid Profile in Experimental Alcoholic Liver Disease. *Mediators Inflamm* 2015; **2015**: 491641 [PMID: 26448681 DOI: 10.1155/2015/491641]
  - 34 **Shi W**, Zhu Q, Gu J, Liu X, Lu L, Qian X, Shen J, Zhang F, Li G. Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism. *Clin Dev Immunol* 2013; **2013**: 253046 [PMID: 24396389 DOI: 10.1155/2013/253046]
  - 35 **Hu X**, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, Toogood PL, Glick GD. Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous ROR $\gamma$  agonists. *Nat Chem Biol* 2015; **11**: 741 [PMID: 26284677 DOI: 10.1038/nchembio0915-741b]
  - 36 **Païdassi H**, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehwet B, Gaboriaud C, Arlaud GJ, Frachet P. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. *J Immunol* 2008; **180**: 2329-2338 [PMID: 18250442 DOI: 10.4049/jimmunol.180.4.2329]
  - 37 **Lu JH**, Teh BK, Wang Ld, Wang YN, Tan YS, Lai MC, Reid KB. The classical and regulatory functions of C1q in immunity and autoimmunity. *Cell Mol Immunol* 2008; **5**: 9-21 [PMID: 18318990 DOI: 10.1038/cmi.2008.2]
  - 38 **Bavia L**, de Castro ÁA, Cogliati B, Dettoni JB, Alves VA, Isaac L. Complement C5 controls liver lipid profile, promotes liver homeostasis and inflammation in C57BL/6 genetic background. *Immunobiology* 2016; **221**: 822-832 [PMID: 26896155 DOI: 10.1016/j.imbio.2016.01.014]
  - 39 **Petrasek J**, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. *J Clin Invest* 2012; **122**: 3476-3489 [PMID: 22945633 DOI: 10.1172/JCI60777]
  - 40 **Martinon F**, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol* 2009; **27**: 229-265 [PMID: 19302040 DOI: 10.1146/annurev.immunol.021908.132715]
  - 41 **MacLaren R**, Cui W, Cianflone K. Adipokines and the immune system: an adipocentric view. *Adv Exp Med Biol* 2008; **632**: 1-21 [PMID: 19025110 DOI: 10.1007/978-0-387-78952-1\_1]
  - 42 **Jiang XL**, Cohen JI, Nagy LE. Pathogenesis of Alcoholic Liver Disease: Interactions between Parenchymal and Non-parenchymal Cells. *Weichangbing Xue* 2011; **16**: 131-134 [DOI: 10.3969/j.issn.1008-7125.2011.03.002]
  - 43 **Leeming DJ**, Veidal SS, Karsdal MA, Nielsen MJ, Trebicka J, Busk T, Bendtsen F, Krag A, Møller S. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. *Scand J Gastroenterol* 2015; **50**: 584-592 [PMID: 25639675 DOI: 10.3109/0365521.2014.996590]
  - 44 **Jeong WI**, Gao B. Innate immunity and alcoholic liver fibrosis. *J Gastroenterol Hepatol* 2008; **23** Suppl 1: S112-S118 [PMID: 18336653 DOI: 10.1111/j.1440-1746.2007.05274.x]
  - 45 **Duddempudi AT**. Immunology in alcoholic liver disease. *Clin Liver Dis* 2012; **16**: 687-698 [PMID: 23101977 DOI: 10.1016/j.cld.2012.08.003]
  - 46 **Baumann M**, Witzke O, Canbay A, Patschan S, Treichel U, Gerken G, Philipp T, Kribben A. Serum C3 complement concentrations correlate with liver function in patients with liver cirrhosis. *Hepatogastroenterology* 2004; **51**: 1451-1453 [PMID: 15362774]
  - 47 **Chong WP**, To YF, Ip WK, Yuen MF, Poon TP, Wong WH, Lai CL, Lau YL. Mannose-binding lectin in chronic hepatitis B virus infection. *Hepatology* 2005; **42**: 1037-1045 [PMID: 16231358 DOI: 10.1002/hep.20891]
  - 48 **Karkampouna S**, Ten Dijke P, Dooley S, Julio MK. TGF $\beta$  signaling in liver regeneration. *Curr Pharm Des* 2012; **18**: 4103-4113 [PMID: 22448681]

- 22630085 DOI: 10.2174/138161212802430521]
- 49 **Hillebrandt S**, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Köhl J, Gressner AM, Matern S, Lammert F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. *Nat Genet* 2005; **37**: 835-843 [PMID: 15995705 DOI: 10.1038/ng1599]
- 50 **Deaciuc IV**, Fortunato F, D'Souza NB, Hill DB, McClain CJ. Chronic alcohol exposure of rats exacerbates apoptosis in hepatocytes and sinusoidal endothelial cells. *Hepatology* 2001; **19**: 306-324 [PMID: 11251313 DOI: 10.1016/S1386-6346(00)00112-1]
- 51 **Miller AM**, Wang H, Park O, Horiguchi N, Lafdil F, Mukhopadhyay P, Moh A, Fu XY, Kunos G, Pacher P, Gao B. Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. *Alcohol Clin Exp Res* 2010; **34**: 719-725 [PMID: 20102572 DOI: 10.1111/j.1530-0277.2009.01141.x]
- 52 **Bajtarek Z**, Józsi M, Bánki Z, Thiel S, Thielens N, Erdei A. Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. *Eur J Immunol* 2000; **30**: 1706-1713 [PMID: 10898508 DOI: 10.1002/1521-4141(200006)30:6<1706::AID-IMMU1706>3.0.CO;2-2]
- 53 **Roychowdhury S**, McMullen MR, Pritchard MT, Hise AG, van Rooijen N, Medof ME, Stavitsky AB, Nagy LE. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. *Hepatology* 2009; **49**: 1326-1334 [PMID: 19133650 DOI: 10.1002/hep.22776]
- 54 **Duffield JS**, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. *J Clin Invest* 2005; **115**: 56-65 [PMID: 15630444 DOI: 10.1172/jci22675]
- 55 **Fallowfield JA**, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, Iredale JP. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. *J Immunol* 2007; **178**: 5288-5295 [PMID: 17404313 DOI: 10.4049/jimmunol.178.8.5288]
- 56 **Nieto N**. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. *Hepatology* 2006; **44**: 1487-1501 [PMID: 17133487 DOI: 10.1002/hep.21427]
- 57 **Helmy KY**, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M. CR1g: a macrophage complement receptor required for phagocytosis of circulating pathogens. *Cell* 2006; **124**: 915-927 [PMID: 16530040 DOI: 10.1016/j.cell.2005.12.039]
- 58 **Hinglais N**, Kazatchkine MD, Mandet C, Appay MD, Bariety J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. *Lab Invest* 1989; **61**: 509-514 [PMID: 2478758]
- 59 **Kumar V**, Ali SR, Konrad S, Zwirner J, Verbeek JS, Schmidt RE, Gessner JE. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. *J Clin Invest* 2006; **116**: 512-520 [PMID: 16453025 DOI: 10.1172/jci25536]
- 60 **Schieferdecker HL**, Rothermel E, Timmermann A, Götze O, Jungermann K. Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. *FEBS Lett* 1997; **406**: 305-309 [PMID: 9136907 DOI: 10.1016/S0014-5793(97)00292-5]
- 61 **Schlaf G**, Schmitz M, Heine I, Demberg T, Schieferdecker HL, Götze O. Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. *Histol Histopathol* 2004; **19**: 1165-1174 [PMID: 15375759 DOI: 10.14670/HH-19.1165]
- 62 **Guo SP**, Zhang WF, Gong JP. Research advance in the origin and immunological function of kupffer cells. *Sheng Li Ke Xue Jin Zhan* 2016; **47**: 57-60 [PMID: 27424408]
- 63 **Enomoto N**, Ikejima K, Yamashina S, Hirose M, Shimizu H, Kitamura T, Takei Y, Sato And N, Thurman RG. Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. *Alcohol Clin Exp Res* 2001; **25**: 51S-54S [PMID: 11410742 DOI: 10.1111/j.1530-0277.2001.tb02418.x]
- 64 **Wheeler MD**, Thurman RG. Up-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathway. *J Biol Chem* 2003; **278**: 8435-8441 [PMID: 12482856 DOI: 10.1074/jbc.M212076200]
- 65 **Schieferdecker HL**, Schlaf G, Jungermann K, Götze O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. *Int Immunopharmacol* 2001; **1**: 469-481 [PMID: 11367531 DOI: 10.1016/S1567-5769(00)00038-2]
- 66 **Reid DT**, Reyes JL, McDonald BA, Vo T, Reimer RA, Eksteen B. Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation. *PLoS One* 2016; **11**: e0159524 [PMID: 27454866 DOI: 10.1371/journal.pone.0159524]
- 67 **Barata L**, Miwa T, Sato S, Kim D, Mohammed I, Song WC. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack. *J Immunol* 2013; **190**: 2886-2895 [PMID: 23390291 DOI: 10.4049/jimmunol.1202536]
- 68 **Laskowski J**, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. *Kidney Int* 2016; **90**: 109-122 [PMID: 27165610 DOI: 10.1016/j.kint.2016.02.036]
- 69 **Liu F**, Wu L, Wu G, Wang C, Zhang L, Tomlinson S, Qin X. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. *Atherosclerosis* 2014; **234**: 237-243 [PMID: 24685815 DOI: 10.1016/j.atherosclerosis.2014.03.004]
- 70 **Vernon KA**, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. *J Am Soc Nephrol* 2016; **27**: 1334-1342 [PMID: 26374608 DOI: 10.1681/ASN.2015030295]
- 71 **Medjeral-Thomas N**, Pickering MC. The complement factor H-related proteins. *Immunol Rev* 2016; **274**: 191-201 [PMID: 27782332 DOI: 10.1111/imr.12477]
- 72 **Faber C**, Williams J, Juel HB, Greenwood J, Nissen MH, Moss SE. Complement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged mice. *Invest Ophthalmol Vis Sci* 2012; **53**: 6324-6330 [PMID: 22918646 DOI: 10.1167/iovs.12-10385]
- 73 **Wilson V**, Darlay R, Wong W, Wood KM, McFarlane J, Schejbel L, Schmidt IM, Harris CL, Tellez J, Hunze EM, Marchbank K, Goodship JA, Goodship TH. Genotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomy. *Am J Kidney Dis* 2013; **62**: 978-983 [PMID: 23870792 DOI: 10.1053/j.ajkd.2013.05.020]
- 74 **Schejbel L**, Schmidt IM, Kirchhoff M, Andersen CB, Marquart HV, Zipfel P, Garred P. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. *Genes Immun* 2011; **12**: 90-99 [PMID: 21270828 DOI: 10.1038/gene.2010.63]
- 75 **Blackall DP**, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. *Am J Clin Pathol* 2004; **121** Suppl: S81-S88 [PMID: 15298153 DOI: 10.1309/06W402EHN GVV24C]
- 76 **McCullough RL**, McMullen MR, Sheehan MM, Poulsen KL, Roychowdhury S, Chiang DJ, Pritchard MT, Caballeria J, Nagy LE. Complement Factor D protects mice from ethanol-induced inflammation and liver injury. *Am J Physiol Gastrointest Liver Physiol* 2018; **315**: G66-G79 [PMID: 29597356 DOI: 10.1152/ajpgi.00334.2017]
- 77 **Wu G**, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. *Circ Res* 2009; **104**: 550-558 [PMID: 19131645 DOI: 10.1161/CIRCRESAHA.108.191361]
- 78 **Wickham SE**, Hotze EM, Farrand AJ, Polekhina G, Nero TL,

- Tomlinson S, Parker MW, Tweten RK. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. *J Biol Chem* 2011; **286**: 20952-20962 [PMID: 21507937 DOI: 10.1074/jbc.M111.237446]
- 79 **Huang Y**, Fedarovich A, Tomlinson S, Davies C. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. *Acta Crystallogr D Biol Crystallogr* 2007; **63**: 714-721 [PMID: 17505110 DOI: 10.1107/s0907444907015557]
- 80 **Podack ER**, Müller-Eberhard HJ. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. *J Immunol* 1978; **121**: 1025-1030 [PMID: 690431]
- 81 **McDonald JF**, Nelsestuen GL. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. *Biochemistry* 1997; **36**: 7464-7473 [PMID: 9200695 DOI: 10.1021/bi962895r]
- 82 **Chu Q**, Liu X, Xiang Y, Liu QW. Study on the structure and function of complement C3. *Zhongguo Mianyixue Zazhi* 2014; **30**: 549-553 [DOI: 10.3969/j.issn.1000-484X.2014.04.031]
- 83 **Liu Q**, Xing G. Complement regulatory proteins and IgA nephropathy. *Zhongguo Shiyong Yike* 2013; **40**: 122-124 [DOI: 10.3760/cma.j.issn.1674-4756.2013.12.059]
- 84 **de Haas CJ**, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. *J Exp Med* 2004; **199**: 687-695 [PMID: 14993252 DOI: 10.1084/jem.20031636]
- 85 **Fujita E**, Farkas I, Campbell W, Baranyi L, Okada H, Okada N. Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a. *J Immunol* 2004; **172**: 6382-6387 [PMID: 15128829 DOI: 10.4049/jimmunol.172.10.6382]
- 86 **Guo RF**, Ward PA. Role of C5a in inflammatory responses. *Annu Rev Immunol* 2005; **23**: 821-852 [PMID: 15771587 DOI: 10.1146/annurev.immunol.23.021704.115835]
- 87 **Nikiforovich GV**, Baranski TJ. Structural models for the complex of chemotaxis inhibitory protein of Staphylococcus aureus with the C5a receptor. *Biochem Biophys Res Commun* 2009; **390**: 481-484 [PMID: 19799858 DOI: 10.1016/j.bbrc.2009.09.113]
- 88 **Otto M**, Hawlisch H, Monk PN, Müller M, Klos A, Karp CL, Köhl J. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. *J Biol Chem* 2004; **279**: 142-151 [PMID: 14570896 DOI: 10.1074/jbc.M310078200]
- 89 **Li BS**, Cui SH, Lv FL, Chen Y, Li YC, Hu CX, Chen CY. Protective effects of complementary peptide of anaphylatoxin C5a on lung injury of experimental sepsis mouse. *Disan Junyi Daxue Xuebao* 2006; **28**: 4 [DOI: 10.3321/j.issn.1000-5404.2006.09.020]
- 90 **Wu Z**, Lv F, Lv C, Wu YZ. Blocking effects of anti-sense peptide of C5a on the adhesion between pulmonary vascular endothelial cell and neutrophil. *Zhongduo Mianyixue Zazhi* 2003; **19**: 5
- 91 **Li L**, Chen L, Zang J, Tang X, Liu Y, Zhang J, Bai L, Yin Q, Lu Y, Cheng J, Fu P, Liu F. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/ $\beta$ -catenin signaling pathway in diabetic kidney disease. *Metabolism* 2015; **64**: 597-610 [PMID: 25682062 DOI: 10.1016/j.metabol.2015.01.014]
- 92 **Lee JH**, Kim H, Ko J, Lee Y. Interaction of C5 protein with RNA aptamers selected by SELEX. *Nucleic Acids Res* 2002; **30**: 5360-5368 [PMID: 12490703 DOI: 10.1093/nar/gkf694]
- 93 **Biesecker G**, Dihel L, Enney K, Bendele RA. Derivation of RNA aptamer inhibitors of human complement C5. *Immunopharmacology* 1999; **42**: 219-230 [PMID: 10408383 DOI: 10.1016/S0162-3109(99)00020-X]

**P- Reviewer:** Marcos M, Metin U, Morales-González JA, Kollmann D  
**S- Editor:** Ma YJ **L- Editor:** Ma JY **E- Editor:** Bian YN





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

